试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-23
Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes
编号:NCT02548494登记状态:提前终止企业 / 申办者:Chattanooga-Hamilton County Hospital Authority
药物 / 成分:Glargine、IV insulin、Electrolyte Correction、Correction of Fluid Loss
登记的停止原因(原文):Project terminated due to insufficient resources for recruitment.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-23
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia
编号:NCT03793712登记状态:提前终止企业 / 申办者:H. Lundbeck A/S
药物 / 成分:Lu AF11167 (1-2 mg/day)、Lu AF11167 (3-4 mg/day)、Placebo
登记的停止原因(原文):Lack of efficacy based on interim analysis
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-23
Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms
编号:NCT03929497登记状态:提前终止企业 / 申办者:H. Lundbeck A/S
药物 / 成分:Lu AF11167
登记的停止原因(原文):Lack of efficacy based on the interim analysis in the 17972A study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-22
Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer
编号:NCT01532362登记状态:提前终止企业 / 申办者:Jonsson Comprehensive Cancer Center
药物 / 成分:Apricoxib
登记的停止原因(原文):Drug sponsor stopped drug manufacture due to toxicity issues from other studies
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-22
Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation
编号:NCT02188719登记状态:提前终止企业 / 申办者:National Institute of Allergy and Infectious Diseases (NIAID)
药物 / 成分:Anti-Thymocyte Globulin - Rabbit、darTreg Infusion、Everolimus、Tacrolimus
登记的停止原因(原文):The trial could not be completed within the grant timeline.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-22
IMT for Primary Clostridium Difficile Infection
编号:NCT02301000登记状态:提前终止企业 / 申办者:Oslo University Hospital
药物 / 成分:Intestinal microbiota therapy、Metronidazole
登记的停止原因(原文):Slow recruitment in pilot phase. A follow-up trial is launched (NCT03796650).
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-22
Anesthetic Techniques in EP Patients
编号:NCT02664922登记状态:提前终止企业 / 申办者:University of California, Los Angeles
药物 / 成分:Propofol、Ketamine、Remifentanil、Sevoflurane
登记的停止原因(原文):Poor study design and too many study groups.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-22
Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) Protocol
编号:NCT02905981登记状态:提前终止企业 / 申办者:Rockwell Medical Technologies, Inc.
药物 / 成分:Fer-In-Sol、Shohl's solution、Triferic
登记的停止原因(原文):Limited subjects, patient compliance
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-22
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis
编号:NCT02943447登记状态:提前终止企业 / 申办者:Gilead Sciences
药物 / 成分:Cilofexor、Placebo to match cilofexor
登记的停止原因(原文):The study was terminated because of the availability of alternate therapies for primary biliary cholangitis (PBC).
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-22
Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis
编号:NCT03473665登记状态:提前终止企业 / 申办者:Columbia University
药物 / 成分:Indomethacin、Diclofenac、Meloxicam、Celecoxib
登记的停止原因(原文):Slow recruitment
查看官方原始记录 ↗